Grant: Alliance Grants
Université Laval
$25,000.00
Microfluidic-based detection of citrate levels in human semen
FY 2024-25
Summary
Prostate cancer is now diagnosed mostly at a localized stage, maximizing patient survival. This is achievable because currently used biomarkers, such as prostate-specific antigen (PSA), are highly sensitive to the presence of prostate cancer. However, PSA shows poor specificity. Indeed, up to two-thirds of men with a positive PSA test will have a negative biopsy. New biomarkers are thus needed to improve the specificity of prostate cancer detection before performing invasive procedures. The goal of the current study is to leverage the metabolic activity of the prostate as a new specific marker of the presence of PCa to avoid unnecessary clinical procedures, reduce side effects, and improve patient quality of life. To this end, we want to build a strong collaboration with a laboratory in the United-States that specializes in lab-on-a-chip development. Our goal is to create a new device that allows biomarker measurements for rapid and specific prostate cancer diagnosis.
Program
Alliance Grants
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
597467-2024
Name nom
Audet-Walsh, Étienne E
Department département
Médecine moleculaire
Organization id
51
Institution établissement
Université Laval
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
25000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
518
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Medical equipment and apparatus
Area of application fr
Appareils et instruments médicaux
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Microfluidic-based detection of citrate levels in human semen
Keywords
citrate; endocrinology; lab-on-a-chip; microfluidics; prostate
Application summary
Prostate cancer is now diagnosed mostly at a localized stage, maximizing patient survival. This is achievable because currently used biomarkers, such as prostate-specific antigen (PSA), are highly sensitive to the presence of prostate cancer. However, PSA shows poor specificity. Indeed, up to two-thirds of men with a positive PSA test will have a negative biopsy. New biomarkers are thus needed to improve the specificity of prostate cancer detection before performing invasive procedures. The goal of the current study is to leverage the metabolic activity of the prostate as a new specific marker of the presence of PCa to avoid unnecessary clinical procedures, reduce side effects, and improve patient quality of life. To this end, we want to build a strong collaboration with a laboratory in the United-States that specializes in lab-on-a-chip development. Our goal is to create a new device that allows biomarker measurements for rapid and specific prostate cancer diagnosis.